● ● ● ● ● ● InteractionsASENAPINERoute and Dosage Schizophrenia:● ● ● ● ● Headache Increased CNS depression with mine, droperidol, gatiflsotalol, thioridazine, chlorpromazine, flExtrapyramidal symptomsDecreased effects of asenapine with dofetilide, dine, Additive effects on QT interval prolongation with InsomniaRestlessnessIncreased effects of Increased hypotension with Drowsiness, dizzinessdepressantsIncreased effects of asenapine with asenapinedine, arsenic trioxide, mefl5 mg 2 times a day. The safety of doses above 10 mg 2 times a or or (Saphris) paroxetine valproateother (^) Class Ia Adults: oxacin, paroxetine PO: andor oquine, dolasetron, tacrolimus, moxiflantihypertensives III antiarrhythmics, pimozide, Usual starting and target dose: or oxacindextromethorphanAntipsychotic Agents alcoholcarbamazepine, cimeti-fl uvoxamine, imipra- oquine, pentama- or other quinidine, ● with CNS^493
2506_Ch28_472-501.indd 1493 2506 Ch 28 472 - 501 .indd 2. Risk for injury related to medication side effects of sedation, 3. Risk for activity intolerance related to medication side effects ● 1 Bipolar Disorder: 4. Noncompliance with medication regimen related to suspi- 1. Risk for other-directed violence related to panic anxiety and 49 day has not been evaluated in clinical trials. 10 mg 2 times a day. The dose can be decreased to 5 mg 2 times a day if there are adverse effects. The safety of doses above 10 mg 2 times a day has not been evaluated in clinical trials. 3 photosensitivity, reduction of seizure threshold, agranulocy-mistrust of others.TO ALL ANTIPSYCHOTIC AGENTSNURSING DIAGNOSES RELATED leptic malignant syndrome, and/or QT prolongation.ciousness and mistrust of others.tosis, extrapyramidal symptoms, tardive dyskinesia, neuro-of sedation, blurred vision, and/or weakness.^ Adults: PO: Recommended initial dose: 1 10/1/10 9:40:12 AM 0 / 1 / 10 9 : 40 : 12 AM
